共 322 条
[1]
Kuroki L(2020)Treatment of epithelial ovarian cancer BMJ (Clinical research ed) 371 m3773-6
[2]
Guntupalli SR(2019)Ovarian Cancer: an Integrated Review Semin Oncol Nurs 35 151-21
[3]
Stewart C(2021)Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment Obstet Gynecol 137 108-15
[4]
Ralyea C(2019)Treatment of recurrent epithelial ovarian cancer Cancer 125 4609-59
[5]
Lockwood S(2020)The forefront of ovarian cancer therapy: update on PARP inhibitors Annals of oncology: official journal of the European Society for Medical Oncology 31 1148-32
[6]
Kurnit KC(2019)Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option Annals of oncology: official journal of the European Society for Medical Oncology 30 721-87
[7]
Fleming GF(2017)Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial Lancet Oncol 18 75-61
[8]
Lengyel E(2017)Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet (London England) 390 1949-95
[9]
Pignata S(2022)Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations Lancet Oncol 23 e314-33
[10]
Pisano C(2021)Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation Eur J cancer (Oxford England: 1990) 159 283-52